Study Design

LUNAR: A phase 3 clinical study comparing the OS benefit in Optune Lua + IOs/docetaxel vs either agent alone1,2

Stratification1

  • IO vs docetaxel 
  • Histology (squamous vs nonsquamous) 
  • Geographic region

Study sites1

  • 130 (North America, Europe, and Asia)

Primary endpoint1

  • OS with Optune Lua + IO or docetaxel vs IO or docetaxel alone

Key secondary endpoints1

  • OS in subpopulations receiving either docetaxel or an IO

*After the interim analysis, the independent data monitoring committee recommended reducing patient accrual to 276 patients with 12 months follow-up.3 
 
Initial accrual was 534 patients with 18 months follow-up. The expected hazard ratio for overall survival is <0.75.1

†Nivolumab, pembrolizumab, or atezolizumab.1

Baseline characteristics: Well balanced across both arms of the study1,3

  • % of patients receiving prior IO 
  • Optune Lua + docetaxel subgroup: 59% 
  • Optune Lua + IO subgroup: 2%

See how to integrate Optune Lua into your practice

Learn more

PD-L1 status reporting was optional and was available for 83% of patients in the United States.4 

One patient had liver and brain metastasis.

§Patients with brain metastases were excluded under the original study design; later amended to allow stable brain metastases.1 

aNSCLC, advanced non-small cell lung cancer; CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; EORTC, European Organisation for Research and Treatment of Cancer; IO, immuno-oncology agent; OS, overall survival; PD-L1, programmed cell death ligand 1; Q6W, every 6 weeks.

 

References: 1. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24(9):1002-1017. doi:10.1016/S1470-2045(23)00344-3 2. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Supplementary appendix. Lancet Oncol. 2023;24(9):1002-1017. doi:10.1016/S1470-2045(23)00344-3 3. Optune Lua. Instructions for Use for non small cell lung cancer. Novocure; 2023. 4. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) after platinum-based therapies: randomized, phase 3 LUNAR study. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract LBA9005.

Editeur du Site :

Novocure France SAS, société anonyme par actions simplifiée au capital de 1 euro, dont le siège social est situé 58 avenue Edouard Vaillant, 92100 Boulogne-Billancourt, France et immatriculée au Registre du Commerce et des Sociétés de Nanterre sous le numéro 853 928 554.

Numéro de téléphone : 01 40 96 06 41

 

Editeur en Chef :

La Directrice de la publication est Mme Anne Calixte de Lembeye, Directrice Générale Novocure France.

 

Hébergeur du Site :

ROI UP AGENCY, S.L.U.-, société á responsabilité unipersonnelle limitée, dont le siège social est situé 70 rue Orense, 28020 Madrid, Espagne et inscrite au Registre du Commerce de Madrid Volume : 28404 Folio : 12 Inscription : 1

Numéro de téléphone : +34 917 707 276

Sites internet Novocure

Les photos contenues dans ce document ont uniquement un but illustratif. Elles ne représentent pas l'état de santé de tous les patients qui pourraient bénéficier d'Optune Lua®.

 

Mise à jour Octobre 2025

©2025 Novocure GmbH. Tout droit réservés. 

Novocure et Optune Lua sont des marques déposées de Novocure GmbH.

FR-OPL-00020 v1.0 Octobre 2025